

2023-2024

American Heart Association

Funding from Pharmaceutical and Biotech Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters, and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations, and estates as well as revenue from the sale of mission-aligned products and services, such as CPR training, and investment earnings.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies and are approved by a committee of national volunteers and executive staff.

Total corporate funding is comprised of unrestricted gifts, special event and program sponsorships and fees from program-related services. Corporate funding represents approximately 15 percent of the AHA's \$1.3 billion total revenue.

Funding that the American Heart Association receives from pharmaceutical and biotech companies and device manufacturers is included within total corporate funding and represents approximately 3 percent of the association's total revenue.

The revenue figures below include the total amount of funds earned or committed to the American Heart Association during fiscal year 2023-2024, noting that, in some cases, the funds will be received in future years. The chart provides funds from pharmaceutical and biotech companies and device manufacturers in proportion to all sources of revenue.



[Schedule of corporate funding provided to the American Heart Association from pharmaceutical and biotech companies and medical device manufacturers during fiscal year 2023-2024.](#)